Clinical Trials Logo

CIN1 clinical trials

View clinical trials related to CIN1.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05372016 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: September 19, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.

NCT ID: NCT04607850 Completed - HPV Infection Clinical Trials

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Start date: March 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.

NCT ID: NCT04425291 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: May 28, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.

NCT ID: NCT03676101 Completed - Vulvar Cancer Clinical Trials

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: October 10, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.

NCT ID: NCT02405533 Completed - Clinical trials for Human Papilloma Virus

Phase II Evaluation of AHCC for the Eradication of HPV Infections

AHCC4HPV
Start date: April 2015
Phase: N/A
Study type: Interventional

This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary outcome of this trial is achieving durable eradication persistent high risk HPV infection determined by HPV negative test results achieved while on active treatment with AHCC and maintained for 6 month post supplementation and 12 months post completion of AHCC treatment compared to placebo.